Financial reports
ARS
2023 FY
Annual report to shareholders
22 Apr 24
10-K
2023 FY
Annual report
28 Mar 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
ARS
2022 FY
Annual report to shareholders
4 Oct 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
10-Q
2023 Q1
Quarterly report
11 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
14 Nov 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
10-Q
2022 Q1
Quarterly report
11 May 22
Current reports
8-K
TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
8-K
Regulation FD Disclosure
27 Mar 24
8-K
TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
22 Mar 24
8-K
TFF Pharmaceuticals Announces Reverse Stock Split
19 Dec 23
8-K
TFF Pharmaceuticals Appoints Thomas B. King to Board of Directors
15 Dec 23
8-K
Departure of Directors or Certain Officers
8 Dec 23
8-K
TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors
4 Dec 23
8-K
Amendments to Articles of Incorporation or Bylaws
22 Nov 23
8-K
TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results
14 Nov 23
8-K
Regulation FD Disclosure
18 Sep 23
Registration and prospectus
S-1/A
IPO registration (amended)
25 Apr 24
S-1
IPO registration
18 Apr 24
S-1
IPO registration
8 Apr 24
D
$1.18 mm in options / securities to be acquired, 2 investors
2 Apr 24
424B5
Prospectus supplement for primary offering
22 Mar 24
S-3/A
Shelf registration (amended)
8 Dec 23
S-3
Shelf registration
21 Nov 23
424B5
Prospectus supplement for primary offering
16 Aug 23
424B5
Prospectus supplement for primary offering
14 Aug 23
424B5
Prospectus supplement for primary offering
27 Jun 23
Proxies
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
DEF 14A
Definitive proxy
4 Oct 23
DEFA14A
Additional proxy soliciting materials
4 Oct 23
PRE 14A
Preliminary proxy
22 Sep 23
DEF 14A
Definitive proxy
27 Dec 22
PRE 14A
Preliminary proxy
15 Dec 22
DEFA14A
Additional proxy soliciting materials
6 Oct 22
DEF 14A
Definitive proxy
21 Sep 22
DEF 14A
Definitive proxy
23 Sep 21
Other
EFFECT
Notice of effectiveness
13 Dec 23
CORRESP
Correspondence with SEC
8 Dec 23
UPLOAD
Letter from SEC
28 Nov 23
EFFECT
Notice of effectiveness
24 Nov 20
CORRESP
Correspondence with SEC
19 Nov 20
UPLOAD
Letter from SEC
9 Nov 20
EFFECT
Notice of effectiveness
16 Sep 20
UPLOAD
Letter from SEC
11 Sep 20
CORRESP
Correspondence with SEC
11 Sep 20
EFFECT
Notice of effectiveness
25 Oct 19
Ownership
4
THOMAS BRAXTON KING
22 Apr 24
4
Michael A Patane
22 Apr 24
4
Catherine Chai-zon Lee
22 Apr 24
4
ROBERT S MILLS
22 Apr 24
4
Brandi Roberts
22 Apr 24
4
KIRK ALLEN COLEMAN
22 Apr 24
4
Zamaneh Mikhak
22 Apr 24
4
STEPHEN ROCAMBOLI
22 Apr 24
4
Harlan F Weisman
22 Apr 24
SC 13G/A
LYTTON LAURENCE W
14 Feb 24